| 2024/04/25 16:59:46 | |
|---|---|
| Price | |
| 1,915.50 DKK | |
| Difference | -2.87% (-56.50) |
General attributes
| ISIN | DK0010272202 |
| Symbol | GMAB |
| Exchange | Nasdaq Copenhagen |
| Currency | DKK |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 16,775 EUR |
| Benchmark | OMX COPENHAGEN 20 |
Market data
| Bid (Bid size) | 1,918.50 DKK (25) |
| Ask (Ask size) | 1,919.00 DKK (28) |
| Open | 1,973.00 DKK |
| High | 1,983.50 DKK |
| Low | 1,915.50 DKK |
| Close (prev. day) | 1,972.00 DKK |
| VWAP | 1,939.492712 DKK |
| Volume (pcs) | 157,995 |
| Trading volume | 305,938,938.25 |
| Number of trades | 5,048 |
| Last size | 141 |
Futures and Options
| Related Futures | 9 |
| Related Options | - |
PDF Downloads
| Company report: GENMAB A/S |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/02/14 |
|
Global Equity Ratings |
|
| 2024/01/23 |
|
Global Equity Ratings |
|
| 2024/04/25 16:59:46 | |
|---|---|
| Price | |
| 1,915.50 DKK | |
| Difference | -2.87% (-56.50) |
General attributes
| ISIN | DK0010272202 |
| Symbol | GMAB |
| Exchange | Nasdaq Copenhagen |
| Currency | DKK |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 16,775 EUR |
| Benchmark | OMX COPENHAGEN 20 |
Market data
| Bid (Bid size) | 1,918.50 DKK (25) |
| Ask (Ask size) | 1,919.00 DKK (28) |
| Open | 1,973.00 DKK |
| High | 1,983.50 DKK |
| Low | 1,915.50 DKK |
| Close (prev. day) | 1,972.00 DKK |
| VWAP | 1,939.492712 DKK |
| Volume (pcs) | 157,995 |
| Trading volume | 305,938,938.25 |
| Number of trades | 5,048 |
| Last size | 141 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -5.92% | -32.19% | -14.90% |
| Perf (abs.) | -120.50 | -909.50 | -335.50 |
| Beta | 0.31 | 0.46 | 0.75 |
| Volatility | 32.84 | 31.63 | 31.09 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 1,986.30 DKK (128,475) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 2,047.66 DKK (106,607) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 2,044.08 DKK (124,339) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 2,326.56 DKK (104,440) |
| YTD High | date | 2,227.00 DKK (2024/01/09) |
| YTD Low | date | 1,825.00 DKK (2024/02/13) |
| 52 Weeks High | date | 2,939.00 DKK (2023/05/23) |
| 52 Weeks Low | date | 1,825.00 DKK (2024/02/13) |
All listings for GENMAB A/S
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Vienna Stock Exchange | 2024/04/25 | 17:32 | 257.40 EUR | 0.00 | 2 |
| Tradegate | 2024/04/25 | 22:26 | 256.70 EUR | 0.09 | 17 |
| Stuttgart | 2024/04/25 | 21:55 | 255.30 EUR | 0.01 | 5 |
| Nasdaq Copenhagen | 2024/04/25 | 16:59 | 1,915.50 DKK | 305.94 | 5,048 |
| Munich | 2024/04/25 | 08:02 | 270.80 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2024/04/25 | 16:55 | 1,933.75 DKK | 24.83 | 2 |
| Hanover | 2024/04/25 | 08:00 | 263.70 EUR | 0.00 | 3 |
| Frankfurt | 2024/04/25 | 21:50 | 254.70 EUR | 0.00 | 3 |
| FINRA other OTC Issues | 2024/04/25 | 21:34 | 269.87 USD | 0.09 | 17 |
| Duesseldorf | 2024/04/25 | 19:31 | 255.40 EUR | 0.00 | 7 |
| Berlin | 2024/04/25 | 21:43 | 256.40 EUR | 0.00 | 16 |
Company Logo
Contact Details
| GENMAB A/S |
| - - |
| Carl Jacobsens Vej 30, Valby - 2500 Copenhagen |
| Telefon: +45-70-20-27-28 |
| Fax: + |
| E-mail: info@genmab.com |
PDF Downloads
| Company report: GENMAB A/S | |
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark. |
Members of Management Board
| Jan G. J. van de Winkel | Chairman of Managing Board |
| Judith Klimovsky | Member of Executive Committee |
| Martine J. van Vugt | Member of Executive Committee |
| Anthony Mancini | Member of Executive Committee |
| Anthony Pagano | Member of Executive Committee |
| Birgitte Stephensen | Member of Executive Committee |
| Christopher Cozic | Member of Executive Committee |
| Tahamtan Ahmadi | Member of Executive Committee |
Board of directors
| Deirdre Connelly | Chairman of Supervisory Board |
| Anders Pedersen | Member of Supervisory Board |
| Mijke Zachariasse | Member of Supervisory Board |
| Paolo Augusto Paoletti | Member of Supervisory Board |
| Elizabeth O'Farrell | Member of Supervisory Board |
| Martin Schultz | Member of Supervisory Board |
| Pernille Erenbjerg | Member of Supervisory Board |
| Rolf K. Hoffmann | Member of Supervisory Board |
| Takahiro Hamatani | Member of Supervisory Board |